Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 280-479-2 | CAS number: 83547-95-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2005
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- REPORTING FORMAT FOR THE ANALOGUE APPROACH
[Please provide information for all of the points below. Indicate if further information is included as attachment to the same record, or elsewhere in the dataset (insert links in 'Cross-reference' table)]
1. HYPOTHESIS FOR THE ANALOGUE APPROACH
[Describe why the read-across can be performed (e.g. common functional group(s), common precursor(s)/breakdown product(s) or common mechanism(s) of action]
2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
[Provide here, if relevant, additional information to that included in the Test material section of the source and target records]
3. ANALOGUE APPROACH JUSTIFICATION
[Summarise here based on available experimental data how these results verify that the read-across is justified]
4. DATA MATRIX
Data source
Reference
- Reference Type:
- other: REACH registration for 2-ethylhexyl mercaptoacetate
- Title:
- Unnamed
- Year:
- 2 005
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 2-ethylhexyl mercaptoacetate
- EC Number:
- 231-626-4
- EC Name:
- 2-ethylhexyl mercaptoacetate
- Cas Number:
- 7659-86-1
- Molecular formula:
- C10H20O2S
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD (SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, North Carolina, USA
- Age at initiation of dose administration: approximately 10 weeks old
- Weight at initiation of dose administration: Males: 322.9-387.3 g; Females: 210.3-261.5 g;
- Housing: individually
- Diet: Certified Rodent Labdiet 5002 ad libitum
- Water: Reverse osmosis-purified (on-site) drinking water ad libitum
- Acclimation period: 15 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21.5-21.6
- Humidity (%): 35.7-40.7
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 9 february 2005 To: 6 July 2005
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Test article formulations were weight/volume (test article/vehicle) formulations. They were prepared approximately weekly as single formulations for each dosage level, divided into aliquots for daily dispensation and stored at room temperature. They were stirred continuously throughout the preparation, sampling and dose administration procedures. They were visually found to be homogeneous and anatically confirmed to be homogeneous.
VEHICLE
- Justification for use and choice of vehicle (if other than water): no
- Concentration in vehicle: 0 (vehicle group), 2 (low), 10 (middle) and 30 mg/mL (high concentration group)
- Amount of vehicle (if gavage): Dosage volume was 5 mL /kg for all groups
- Purity: 100% - Details on mating procedure:
- - M/F ratio per cage: 1/1
- Length of cohabitation: 14 days
- Proof of pregnancy: vaginal plug or sperm in vaginal smear, referred to as day 0 of pregnancy
- After successful mating each pregnant female was caged (how): in plastic maternity cages with nesting material, ground corncob bedding. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Resuspension homogeneity and 11-day stability were established in a previous study. Samples for concentration analysis were collected from the middle stratum of each formulation (including control) every 2 weeks.
- Duration of treatment / exposure:
- Exposure period: Males received 15 daily doses prior to mating. Males were dosed throughout the mating period for a total of 54 doses. Females received a minimum of 15 daily doses prior to pairing and were dosed through lactation.
Duration of test substance (TS) exposure: males 54 days; females 41-44 days - Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 10 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 12
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
Dose levels were selected based on the results of a previous study. In that study, 1 female in the 150 mg/kg/d group was found dead on study day 2. Effects on the mean bodyweight, on food consumption and liver and kidney weights were also observed at this level in both sexes. Increased liver and kidney weights were also observed in the males of the 50 mg/kg/d group.
- Rationale for animal assignment: no (randomization). - Positive control:
- No
Examinations
- Parental animals: Observations and examinations:
- CLINICAL OBSERVATIONS AND SURVIVAL: Yes
All rats were observed twice daily, once in the morning and once in the afternoon‘ for mori bundity and mortalitv. Individual detailed clinical observations were recorded weekly (prior to test article administration during the treatment period). Each male and female was also observed for signs of toxicity at the time of dosing and approximately 1-2 hours following dose administration. AlI significant findings were recorded. Observations included, but were not limited to, evaluations for changes in appearance of the skin and fur, eyes and mucous membranes, respiratory, circulatory, autonomic and central nervous system functions, somatomotor activity and behavior patterns. During the period of expected parturition, the females were observed twice daily for initiation and completion of parturition and for signs of dystocia. Individual gestation length was calculated using the date delivery started.
BODY WEIGHT: Yes
Individual male body weights were recorded weekly, beginning prior to treatment on the first day of dose administration, throughout the study and prior to the scheduled euthanasia. Individual female body weights were recorded weekly, beginning on the first day of dose administration, until evidence of copulation was observed. Once evidence of mating was observed, female body weights were recorded on gestation days 0, 4, 7, 11, 14, 17 and 20 and on lactation days 1 and 4.
FOOD CONSUMPTION: Yes
Individual food consumption was recorded on the corresponding weekly body weight days until pairing. Food intake was not recorded during the mating period. Once evidence of mating was observed, female food consumption was recorded on gestation days 0, 4, 7, 11, 14, 17and 20 and on lactation days 1 and 4. Following mating, food consumption for males was measured on a weekly basis until the scheduled euthanasia. - Oestrous cyclicity (parental animals):
- Not done
- Sperm parameters (parental animals):
- Not done
- Litter observations:
- LITTER VIABILITY AND DEATHS
Each litter was examined dailv for survival, and all deaths were recorded. A daily record of litter size was maintained. Intact offspring dying were necropsied using a fresh dissection technique including the heart and major vessels Tissues were preserved in 10% neutral-buffered formalin for possible future histopathologic examination only as deemed necessary by Ithe gross findings. The carcass of each pup was then discarded.
CLINICAL OBSERVATIONS
Litters were examined daily for survival and any adverse changes in appearance or behavior. Each pup received a detailed physical examination on PND 1 and 4. Any abnormalities in nursing behavior were recorded.
BODY WEIGHTS
Pups were individually weighed on PND 1 and 4.
SEX DETERMINATION
Pups were individually sexed on PND 1 and 4. - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals at day 54 after the first day of treatment
- Maternal animals: All surviving animals at post-mating day 25 or at lactation day 4.
GROSS NECROPSY
- Gross necropsy consisted of examination of external surface, all orifices, the cranial cavity, the external surface of the brain, and the thoracic, abdominal and pelvic cavities, including viscera. Females that delivered were euthanized on lactation day 4, the number of former implantation sites and corpora lutea were recorded. Females that failed to deliver were euthanized on postmating day 25 (females with evidence of mating). Uteri with no macroscopic evidence of implantation were opened and subsequently placed in 10% ammonium sulfide solution for detection of early implantation loss (Salewski. 1964).
ORGAN WEIGHTS
The following organs were weighed from all F0 animals at the scheduled necropsies:
Brain
Epididymides
Kidnevs
Liver
Ovaries with oviducts
Pituitary gland
Testes
HISTOPATHOLOGY
Ovaries with oviducts, pituitary gland, testes, epididymides were prepared for microscopic examination. Coagulating glands, mammary gland, prostate gland, seminal vesicle, uterus with vagina and cervix and all gross lesions were prepared for microscopic examination. Selected tissues were examined microscopically from all F0 animals in the control and high-dose groups. The vagina and cervix were also examined from each female in the 10 and 50 mg/kg/day groups. - Postmortem examinations (offspring):
- SACRIFICE
- The F1 offspring were sacrificed at 4 days of age following an external examination and discarded without further evaluation. - Statistics:
- Analyses were conducted using two-tailed tests (except as noted otherwise) for minimum significance levels of 1% and 5%, comparing each test group to the control group by sex. Statistical analyses were not conducted if the number of animals was two or less. Data obtained from nongravid females were excluded from statistical analyses following the mating period. Where applicable, the litter was used as the experimental unit.
Parental mating, fertility, conception and copulation indices were analyzed using the Chi-square test with Yates' correction factor (Hollander and Wolfe, 1999). Mean parental body weights (weekly, gestation and lactation), body weight changes and food consumption, offspring body weights and body weight changes, gestation length, number of implantation sites, number of corpora lutea, number of pups born, live litter size on Post Natal Day (PND) 0, unaccounted-for sites, absolute and relative organ weights, and pre-coital intervals values were subjected to a parametric one-way analysis of variance (ANOVA) (Snedecor and Cochran. 1980) to determine intergroup differences. If the ANOVA revealed statisticallv significant (p<0.05) intergroup variance, Dunnett's test (Dunnett, 1964) was used to compare the test groups to the control group.
Mean litter proportions (percent per litter) of males at birth and postnatal survival were subjected to the Kruskal-Wallis nonparametric ANOVA test (Kruskal and Wallis, 1952) to determine intergroup differences. If the ANOVA revealed statistically significant (p<0.05) intergroup variance, Dunn's test (Dunn, 1964) was used to compare the test groups to the control group. - Reproductive indices:
- Mating, fertility and copulation/conception indices were calculated.
- Offspring viability indices:
- Mean live litter size and postnatal survival were calculated.
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Salivation and/or clear material around the nose and/or mouth was observed in the 50 mg/kg/day group males and the 150 mg/kg/day group males and females at the time of dose administration and/or approximately 1-2 hours following dose administration.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Three males in the 150 mg/kg/day group were found dead or euthanized in extremis due to excessive body weight loss on study days 4 or 14. Two of them had decreased defecation and an unkempt appearance the day of or prior to euthanasia on study day 14. Three females in the 150 mg/kg/day group were found dead or euthanized in extremis on gestation day 21 or 22. On gestation day 22, one female exhibited signs of dystocia: hypoactivity, an unkempt appearance, piloerection, soft stool, drooping eyelids, hypothermia (cool to the touch) and was recumbent and unresponsive to handling; consequently, this female was euthanized later that day. In addition one female in the 150 mg/kg/day group was euthanized on lactation day 1 due to total litter loss.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Males:
Mean body weight gain was reduced (statistically significant, p<0.01) in the 150 mg/kg/day group during the pre-mating period (study days 0-14) compared to that in the control group, resulting in reduced (not statistically significant) mean body weight gains when the entire treatment period (study days 0-54) was evaluated. Mean body weights and body weight gains in the 10 and 50 mg/kg/day group males were similar to those in the control group throughout the study. None of the differences were statistically significant.
Females:
No statistical change was elicited during pre-mating and lactation periods. During gestation days 14-17 and 17-20, mean body weight gains in the 150 mg/kg/day group
females were reduced compared to those in the control group; the difference was statistically significant (p<0.05) during gestation days 17-20. - Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Males:
An increase in food consumption was observed during the post-mating period. It was attributed to the weight loss.
Females:
No statistical difference in food consumption was attributed to treatment. - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- The 2 males that were euthanized in extremis and 1 of the females that was found dead had test article-related findings (periportal or generalized hepatocellular vacuolation) in the liver. This finding was characterized by the presence of numerous small, round, clear vacuoles within the hepatocellular cytoplasm, which distended the affected cells and gave the cytoplasm a foamy appearance. Affected cells were limited to the areas immediately surrounding portal triads (periportal hepatocellular vacuolation) or affected hepatocytes in a diffuse manner without apparent zonal distribution (generalized hepatocellular vacuolation). This finding correlated with the macroscopic findings (white areas or pale liver) observed in these animals that were found dead/euthanized in extremis and with increased relative liver weights observed in animals at the scheduled necropsy. Livers were not scheduled to be retained/examined at the scheduled necropsy. Therefore, further investigation of this finding at the scheduled necropsy was not possible.
Mucification of the cervical and vaginal epithelium was noted microscopically in the 150 mg/kg/day group gravid females that died or were euthanized in extremis prior to the scheduled necropsy on lactation day 4. This finding may be a morphologically normal peri-parturitional phenomenon, but since there were no control group animals examined at that age, this cannot be unequivocally established. However. there was a dose-related increase in incidence and severity of mucification compared to the control group at the scheduled necropsy on lactation day 4 (1/11 (9.1%), 3/12 (25%), 3/10 (30%) and 4/6 (67%) of the gravid females in the control, 10, 50 and 150 mg/kg/day groups, respectively). Taken in context of the maternal mortality, dystocia and adverse effects on pup growth and survival, mucification of the vaginal epithelium in the 150 mg/kg/day group was considered test article-related.
All other microscopic changes were consistent with normal background lesions in clinically normal rats of the strain and age used in this study, and were considered to be spontaneous and/or incidental in nature and unrelated to test article administration. - Histopathological findings: neoplastic:
- not examined
- Other effects:
- not specified
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- REPRODUCTIVE PERFORMANCE
No test article-related effects on F0 reproductive performance were observed at any dosage level.
Male and female mating indices were 100.0% in all groups.
Male fertility indices were 91.7, 100.0, 83.3 and 100.0% and female fertility indices were 91.7, 100.0, 83.3 and 83.3% in the control, 10, 50 and 150 mg/kg/day groups, respectively.
Male copulation indices were 91.7, 100.0, 83.3 and 100.0% and female conception indices were 91.7, 100.0, 83.3 and 83.3% in the same respective groups.
No statistically significant differences were noted between the control and test article-treated groups. Males that did not sire a litter numbered 1, 0, 2 and 0 in the control, 10, 50 and 150 mg/kg/day groups, respectively.
Females that had evidence of mating but were nongravid numbered 1, 0, 2 and 2 in the same respective groups.
The mean numbers of days between pairing and coitus in the test article-treated groups were similar to the control group value. None of these differences were statistically significant.
The mean number of pups born in the 150 mg/kg/day group (13.3 per dam) was slightly (not statistically significant) lower than the control group value (15.5 per dam).
Mean live litter size on PND 0 in the 150 mg/kg/day group (12.7 pups per dam) was decreased compared to the control group value (15.3 pups per dam). The difference was not statistically significant.
GESTATION LENGTH AND PARTURITION
Mean gestation lengths in the 10, 50 and 150 mg/kg/day groups were similar to those in the control group.
Signsof dystocia were observed in female no. 74656 (euthanized in extremis on gestation day 22 in the 150 mg/kg/day group). On the day of expected parturition, this female was hypoactive, had an unkempt appearance, piloerection, soft stool, drooping eyelids, hypothermia, was recumbent and unresponsive to handling. In addition, 2 other females in this group were found dead 1 day prior to the expected day of parturition (gestation day 21).
Effect levels (P0)
- Dose descriptor:
- NOAEL
- Effect level:
- 50 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- mortality
- body weight and weight gain
- food consumption and compound intake
- organ weights and organ / body weight ratios
- histopathology: non-neoplastic
Target system / organ toxicity (P0)
- Critical effects observed:
- no
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- The percentage of males at birth in the treated groups was unaffected.
- Mortality / viability:
- mortality observed, treatment-related
- Description (incidence and severity):
- Pups (Iitters) that were found dead numbered 2(2), 2(2), 2(2) and 23(4) in the control‘10, 50 and 150 mg/kg/day groups. respectively. In the 150 mg/kg/day group, 4 pups were missing and presumed to have been cannibalized and 7 pups were small: these findings were considered to be test article-related. The general physical condition of pups in the 10 and 50 mg/kg/day groups was unaffected by test article administration.
A reduction (not statistically significant) in postnatal survival in the 150 mg/kg/day group (93.8% per litter) was observed on PND 0 (relative to the number born) compared to the control group value (98.9% per litter). Mean postnatal survival in this group (82.1 % per litter) was reduced during PND 0-1 (not statistically significant) compared to the control group value (100.0% per litter). This decrease was largely due to female no. 74640 that had total litter loss on PND 1 (17 pups): however, dead pup was found in each of 3 other litters at that time. Postnatal survival in the 150 mg/kg/day group was similar to that in the control group during PND-4. However. when the entire postnatal period (birh to PND 4) was evaluated, postnatal survival in this group (73 .2% per litter) was reduced compared to that in the control group (98.9% per litter). The difference was statistically significant (p<0.05). The effects on postnatal survival in this 150 mg/kg/day group were considered test article-related. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Mean body weights in the 150 mg/kg/day group pups were decreased (10.0%-17.2%, males and 13.6%-18.3%, females) compared to the control group values on PND 1 and 4; the majority of the differences were statistically significant (p<0.05). Mean male and female pup body weight gains during PND 1-4 in this group were reduced compared to those in the control group: the difference was not statistically significant. The reductions in pup body weights and body weight gains were attributed to the test article.
Mean male and female pup body weights and body weight changes in the 10 and 50 mg/kg/day groups were unaffected during PND 1-4. No statistically significant differences from the control group were noted. - Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Of the pups (litters) found dead during PND 0-4 numbered 0(0), 1(1) and 18(2) were too autolyzed to examine and of the remaining pups (litters), 1(1), 2(2), 1(1) and 5(2) had no presence of milk in the stomach in the control, 10, 50 and 150 mg/kg/day groups, respectively. No other internal findings were noted.
- Histopathological findings:
- not examined
- Other effects:
- not specified
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not examined
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not examined
Effect levels (F1)
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 50 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- viability
- body weight and weight gain
Target system / organ toxicity (F1)
- Critical effects observed:
- no
Overall reproductive toxicity
- Reproductive effects observed:
- yes
- Lowest effective dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- Treatment related:
- yes
- Relation to other toxic effects:
- reproductive effects as a secondary non-specific consequence of other toxic effects
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
Applicant's summary and conclusion
- Conclusions:
- In this study parental systemic toxicity was observed in the 150 mg/kg/day group. It was characterized by: mortality, moribundity, decreased mean body weight gain, decreased consumption of feed, increased liver and kidney weight or hepatocellular vacuolization in at least one sex of the F0 animals: and increased mucification of the cervical and vaginal epithelium in post-partum F0 dams. Decreased viability and growth of the F1 animals through post-partum day 4 also occurred at the 150 mg/kg/day dose. Within the limits of the experimental design, a dosage level of 50 mg/kg/day was considered to be the no-observed-adverse-effect level (NOAEL) for reproductive, developmental, systemic and neonatal toxicity resulting from exposure to 2-ethylhexyl mercaptoactetate when administered orally by gavage to rats.
- Executive summary:
In an OECD guideline 421 study, groups of 12 male and female rats were exposed to doses of EHTG of 0, 10, 50 and 150 mg/kg bw/day by gavage (WIL, 2005). Males received 15 daily doses prior to mating. Males were dosed throughout the mating period through 1 day prior to euthanasia for a total of 54 doses. Females received a minimum of 15 daily doses prior to pairing and were dosed through lactation. All animals were observed twice daily for mortality and morbidity. Clinical observations, body weights and food consumption were recorded at appropriate intervals. All F0 females were allowed to deliver and rear their pups until lactation day 4. The F0 females were euthanized on lactation day 4 and the F0 males were euthanized following completion of the necropsies of the F0 females. Complete necropsies were conducted on all F0 animals, and selected organs were weighed. Selected tissues were examined microscopically from all F0 animals in the control and high-dose groups and females in the low and mid-dose groups. F1 clinical observations and body weights were recorded on postnatal days (PND) 1 and 4. Pups were euthanized on PND 4 following an external examination and discarded without further evaluation.
Three males and 3 females in the 150 mg/kg-bw/day group were found dead or euthanized in extremis. Prior to death/euthanasia, 2 of these males and 1 female had marked body weight losses; these males also had decreased defecation, unkempt appearance and/or red or yellow material on various body surfaces. The female that was euthanized in extremis had signs of dystocia. These premature deaths were attributed to the test article. In addition, 1 female in the 150 mg/kg-bw/day group was euthanized due to total litter loss on lactation day 1. All other animals survived to the scheduled necropsies. There were no test article-related clinical findings in the 10 mg/kg-bw/day group males and females or in the 50 mg/kg-bw/day group females. There were no test article-related effects on male and female mating and fertility indices, male copulation index or female conception index. The mean number of days between pairing and coitus in the test article-treated groups were similar to the control group value.
Mean body weights and/or body weight gains in the 150 mg/kg-bw/day group males were generally reduced throughout the study. Mean food consumption in these males was similar to that in the control group during the pre- and post-mating periods. During the pre-mating period, no test article-related effects on body weight gain and food consumption were observed in the 150 mg/kg-bw/day group females. However, mean maternal body weight gain in these females was lower during gestation days 17-20; the reduction was attributed to a female with a small litter size and 1 of the females that was found dead on gestation day 21. Gestation food consumption was unaffected by test article administration in this group. During lactation, mean body weight gain and food consumption in the 150 mg/kg/day group were similar to that in the control group. There were no test article-related effects on mean body weights or food consumption in the 10 and 50 mg/kg-bw/day group males and females throughout the study.
Mean gestation lengths in the test article-treated groups were similar to that in the control group. Two females in the 150 mg/kg-bw/day group were found dead on gestation day 21, near the time of expected parturition, 1 female was euthanized in extremis on gestation day 22 with signs of dystocia, and 1 female was euthanized due to total litter loss on lactation day 1.
Mucification of the cervical and vaginal epithelium was noted microscopically in the 150 mg/kgbw/ day group gravid females that died or were euthanized in extremis prior to the scheduled necropsy on lactation day 4. This finding may be a morphologically normal peri-parturitional phenomenon, but since there were no control group animals examined at that age, this cannot be unequivocally established. However, there was a dose-related increase in incidence and severity of mucification compared to the control group at the scheduled necropsy on lactation day 4. Although this finding itself was not considered abnormal morphologically, its presence on lactation day 4 was clearly increased compared to the control group. Taken in context of the maternal mortality, dystocia and adverse effects on pup growth and survival, mucification of the vaginal epithelium in the 150 mg/kg-bw/day group was considered test article-related. No test article-related effects on the mean numbers of corpora lutea, implantation sites or unaccounted-for sites were observed at any dosage level. Slight reductions in the mean numbers of corpora lutea and implantation sites were observed in the 150 mg/kg-bw/day group. The decreases resulted in a reduced mean number of pups born and corresponded to lower mean maternal body weight gain late in gestation. These slight reductions in mean numbers of corpora lutea and implantation sites and the number of pups born was not considered test article-related as these decreased mean values were attributed primarily to a single female with only 8 corpora lutea.Macroscopic changes in the liver that correlated to hepatocellular vacuolization were observed in 2 males and 1 female in the 150 mg/kg/day that were found dead or euthanized in extremis. At the scheduled necropsies, no test article-related macroscopic lesions were observed, including in the liver. However, mean relative (to final body and brain weight) liver weights in the 150 mg/kg/day group males and females were increased, and the increase was considered related to the lesions observed in the unscheduled death animals. Mean relative (to final body weight) kidney weight was increased in the 150 mg/kg/day group males. EHTG reduced post-natal survival at 150 mg/kg-bw/day but was not teratogenic. There were no test article-related effects on the general physical condition of the pups or pup body weights in the 10 and 50 mg/kg/day groups. At the necropsy of pups that were found dead, there were no internal findings that were related to parental treatment with the test article.At doses producing maternal mortality, EHTG is considered to have a reproductive effect (dystocia in the 150 mg/kg-bw/day group was considered test article-related). Within the limits of the experimental design, a dosage level of 50 mg/kg-bw/day was considered to be the NOAEL for reproductive effects and systemic (maternal) toxicity resulting from exposure to EHTG when administered orally by gavage to rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.